- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04363242
A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions
April 10, 2023 updated by: Synermore Biologics Co., Ltd.
A Phase 1 Dose Escalation Trial of SYN125 Single Agent in Solid Tumors and in Combination With Fixed Dose SYN004 in Patients With Epithelial Cancers With EGFR Expressions.
A Phase 1 Dose Escalation Trial of SYN125 Single Agent in the Treatment of Solid Tumors and in Combination With Fixed Dose SYN004 in Patients With Cancer of the Internal or External Lining of the Body.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Humans have an immune system that can protect and fight infections and abnormal cells.
T-cells are a type of cell produced by the body that can attack and kill cancer cells.
Unfortunately, many cancer cells have ways preventing T-cells from working properly.
SYN125 and SYN004 can make T-cells work again.
This is a study to find the maximum tolerated dose of SYN125 when it is used as a single treatment (Part A) for solid tumors, and when it is used as a combined treatment with a fixed dose of SYN004 (Part B), in patients with epithelial cancers with EGFR (epithelial growth factor receptor) expressions.
Study Type
Interventional
Enrollment (Actual)
22
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kansas
-
Fairway, Kansas, United States, 66205
- University of Kansas Cancer Center, Clinical Research Center, 4350 Shawnee Mission Parkway, MS 6004
-
-
Michigan
-
Brownstown, Michigan, United States, 48183
- Henry Ford Health System, Henry Ford Hospital
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma, Peggy and Charles Stephenson Cancer Center, 800 Northeast 10th Street
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Signed informed consent form.
- Have documented diagnosis of recurrent or metastatic solid tumors for whom no standard treatment options are available (Part A only).
- Have epithelial cancers which have endothelial growth factor receptor (EGFR) expressions (not necessarily mutated or over-expressed) (Part B only).
Note: Prior EGFR (epidermal growth factor receptor) therapy and approved checkpoint inhibitor therapy are allowed but not required.
- Prior anti-PD-1 (programmed cell death 1), anti-PD-L1 (programmed death-ligand 1), anti-PD-L2 (programmed death-ligand 2), anti-cytotoxic T-lymphocyte antigen (CTLA-4) are allowed, where the wash-out period will be 28 days from last dose of previous therapy except for palliative RT and smaller molecular oral therapeutic agents where 5 half-lives or 28 days, whichever is shorter, will apply (Part A and Part B).
- Have evaluable disease per modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1) for immune based therapeutics (iRECIST).
- Have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1.
- Adequate bone marrow function, with absolute neutrophil count >1,500/µL, platelet count >75,000/µL, and hemoglobin >9g/dL (or 5.6 mmol/L).
- Adequate liver function with bilirubin <1.5 x the upper limit of normal (ULN) range, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5 x the ULN.
- Adequate renal function, as defined by having creatinine clearance ≥30 mL/min calculated by either Cockcroft-Gault or Modification of Diet in Renal Disease equations.
- Adequate cardiac function, no clinically significant abnormalities assessed by electrocardiogram (ECG), and absence of significant cardiac disease.
- Negative serum pregnancy test within 24 hours prior to start of study drug in female patients of childbearing potential. Not applicable to patients unable to become pregnant, including those with bilateral oophorectomy and/or hysterectomy or postmenopausal.
- Patients of childbearing potential must be using highly effective contraception consisting of 2 forms of birth control (at least 1 of which must be a barrier method) during heterosexual intercourse, starting at screening and continuing throughout study, for a total of 31 weeks post-treatment completion.
Exclusion Criteria:
- Have ongoing toxicities >Grade 1 according to NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) v5.0 (excluding alopecia and neuropathy).
- Have any contraindications to receiving cetuximab therapy, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 (anti-cytotoxic T-lymphocyte antigen) antibody, or other antibody or drug targeting T-cell co-stimulation or immune checkpoint pathways.
- Have known hypersensitivity to study drugs.
- Have undergone surgery and not recovered adequately from toxicities and/or complications from the intervention prior to starting study therapy; or have unresolved toxicity from prior radiation, chemotherapy, or other targeted treatment, including investigational treatment.
- Have clinically significant cardiac arrhythmia, unless well-controlled.
- Have clinically active central nervous system metastases and/or carcinomatous meningitis. Patients with previously treated brain or meningeal metastasis may participate and be eligible for treatment provided they are stable and asymptomatic, and have no evidence of new or enlarging brain metastases evaluated within 4 weeks prior to the first dose of study drug.
Patients with history of human immunodeficiency virus (HIV) and:
- CD4+ T-cell count is ≤350 cells µL;
- History of AIDS-defining opportunistic infection within the past 12 months;
- Antiretroviral therapy <4 weeks and HIV viral load >400 copies/mL.
- Have participated in another investigational drug or device study within 4 weeks of the first dose of study drug.
- Female patient who is pregnant or breast feeding.
- Have signs or symptoms of organ failure, major chronic illnesses other than cancer, or any concomitant medical or social condition that, in the opinion of the investigator, make it undesirable for the patient to participate in the study, or that could jeopardize compliance with the protocol.
Other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A
Dose escalation of SYN125.
Each dose level (low, medium, high) will be tested in a cohort of 3 patients.
If no dose-limiting toxicity (DLT) is observed in the 3 patients, dose escalation will continue to the next SYN125 dose level.
|
Administered by IV infusion
|
Experimental: Part B
Dose escalation of SYN125 administered with a fixed-dose of SYN004 (SYN004 will be administered immediately after SYN125 infusion is complete, if tolerated).
Once cohorts with low and medium dose levels in Part A are completed and no DLTs are observed per cohort, Part B with the SYN125 low dose level + SYN004 will start and run in parallel with Part A. The high dose of SYN125 in a cohort in Part A will begin along with Part B.
|
Administered by IV infusion
Administered by IV infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A: Incidence of dose-limiting toxicities (DLTs)
Time Frame: Up to Day 28
|
Incidence of DLTs with single agent SYN125
|
Up to Day 28
|
Part B: Incidence of dose-limiting toxicities (DLTs)
Time Frame: Up to Day 28
|
Incidence of DLTs with SYN125 and fixed-dose SYN004 administered in combination
|
Up to Day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse Events (AEs)
Time Frame: Up to Day 50
|
Incidence of Adverse Events (AEs)
|
Up to Day 50
|
Incidence of Clinical Laboratory Abnormalities
Time Frame: Up to Day 50
|
Defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0)
|
Up to Day 50
|
Serum concentration time profiles (Area under the serum concentration-time curve from time zero to the last measurable concentration)
Time Frame: Up to Day 106
|
Serum concentration time profiles (Area under the serum concentration-time curve from time zero to the last measurable concentration) of SYN125 and SYN004
|
Up to Day 106
|
Area under the serum concentration time-curve over the dosing interval
Time Frame: Up to Day 106
|
Area under the serum concentration time-curve over the dosing interval of SYN125 and SYN004
|
Up to Day 106
|
Area under the serum concentration-time curve from time zero extrapolated to infinity (AUC0-inf)
Time Frame: Up to Day 106
|
Area under the serum concentration-time curve from time zero extrapolated to infinity (AUC0-inf) of SYN125 and SYN004
|
Up to Day 106
|
Maximum Observed Plasma Concentration (Cmax)
Time Frame: Up to Day 106
|
Maximum Observed Plasma Concentration (Cmax) of SYN125 and SYN004
|
Up to Day 106
|
Time to maximum observed serum concentration (Tmax)
Time Frame: Up to Day 106
|
Time to maximum observed serum concentration (Tmax) of SYN125 and SYN004
|
Up to Day 106
|
Terminal elimination half-life (t1/2)
Time Frame: Up to Day 106
|
Terminal elimination half-life (t1/2) of SYN125 and SYN004
|
Up to Day 106
|
Clearance
Time Frame: Up to Day 106
|
Clearance of SYN125 and SYN004
|
Up to Day 106
|
Volume of distribution at steady-state (Vss)
Time Frame: Up to Day 106
|
Volume of distribution at steady-state (Vss) of SYN125 and SYN004
|
Up to Day 106
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 9, 2020
Primary Completion (Anticipated)
July 31, 2023
Study Completion (Anticipated)
September 30, 2023
Study Registration Dates
First Submitted
April 23, 2020
First Submitted That Met QC Criteria
April 23, 2020
First Posted (Actual)
April 27, 2020
Study Record Updates
Last Update Posted (Actual)
April 12, 2023
Last Update Submitted That Met QC Criteria
April 10, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SYN125-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
Pyxis Oncology, IncRecruiting